person · Reporting owner

Vessey Rupert

Disclosed activity across 5 companies

Tapewire entity: 15357
SEC CIK: 0001677618

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BIO-TECHNE CorpTECH · Entity 3479	Director	October 30, 2025	November 03, 2025
BRISTOL MYERS SQUIBB COBMY · Entity 1662	EVP & President, Research	May 03, 2023	May 04, 2023
Generate Biomedicines, Inc.GENB · Entity 1553	Director	February 26, 2026	March 02, 2026
Juno Therapeutics, Inc.JUNO · Entity 168572	Director	April 13, 2017	April 19, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIO-TECHNE Corp

Report date October 30, 2025 · Filed November 03, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,987	Reported balance After 2025-10-30 transaction · row 1 1 source row Row 1 · 2025-10-30 · Grant · Acquired 1,640 · Balance 10,987
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.96 · Expires 2035-10-30	Direct	3,777	Reported balance After 2025-10-30 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-10-30 · Grant · Acquired 3,777 · Balance 3,777 F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.41 · Expires 2029-10-24	Direct	8,044	Reported balance Holding disclosure · report date 2025-10-30 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 8,044
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.32 · Expires 2029-06-30	Direct	2,352	Reported balance Holding disclosure · report date 2025-10-30 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 2,352
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.92 · Expires 2030-10-29	Direct	6,028	Reported balance Holding disclosure · report date 2025-10-30 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 6,028
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.81 · Expires 2031-10-28	Direct	2,532	Reported balance Holding disclosure · report date 2025-10-30 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 2,532
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.94 · Expires 2032-10-27	Direct	3,460	Reported balance Holding disclosure · report date 2025-10-30 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance 3,460
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.51 · Expires 2033-10-26	Direct	3,937	Reported balance Holding disclosure · report date 2025-10-30 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance 3,937
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.37 · Expires 2034-10-24	Direct	3,511	Reported balance Holding disclosure · report date 2025-10-30 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance 3,511

Filing footnotes · ownership attribution and instrument terms

F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

BRISTOL MYERS SQUIBB CO

Report date May 03, 2023 · Filed May 04, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.10 par valueSEC Table I · non-derivative	Direct	47,751	Reported balance After 2023-05-03 transaction · row 1 1 source row Row 1 · 2023-05-03 · Sale · Disposed 50,385 · Balance 47,751 F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $67.050 to $67.111, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Common Stock, $0.10 par valueSEC Table I · non-derivative	IndirectBMS Savings and Investment Program	655.73	Reported balance Holding disclosure · report date 2023-05-03 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 655.73 F2: Based on recent 401(k) plan statement.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $67.050 to $67.111, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

F2: Based on recent 401(k) plan statement.

Generate Biomedicines, Inc.

Report date February 26, 2026 · Filed March 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-25	Direct	29,561	Reported balance After 2026-02-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-26 · Grant · Acquired 29,561 · Balance 29,561 F1: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

Juno Therapeutics, Inc.

Report date April 13, 2017 · Filed April 19, 2017

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CELGENE CORP /DE/

Report date November 20, 2019 · Filed November 22, 2019

Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2019-11-20 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2019-11-20 · Grant · Acquired 8,634 · Balance 22,812 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 2 · 2019-11-20 · Grant · Acquired 13,906 · Balance 36,718 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 3 · 2019-11-20 · Grant · Acquired 24,209 · Balance 60,927 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 4 · 2019-11-20 · Disposition to issuer · Disposed 60,927 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Common StockSEC Table I · non-derivative	Indirect401(k) Plan	Reported balance After 2019-11-20 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2019-11-20 · Disposition to issuer · Disposed 613 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $118.57 · Expires 2025-02-02	Direct	Reported balance After 2019-11-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-11-20 · Disposition to issuer · Disposed 19,142 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $109.90 · Expires 2025-05-04	Direct	Reported balance After 2019-11-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $132.56 · Expires 2025-07-27	Direct	Reported balance After 2019-11-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.08 · Expires 2025-11-09	Direct	Reported balance After 2019-11-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.80 · Expires 2026-02-01	Direct	Reported balance After 2019-11-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-11-20 · Disposition to issuer · Disposed 2,344 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.97 · Expires 2026-05-02	Direct	Reported balance After 2019-11-20 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2019-11-20 · Disposition to issuer · Disposed 9,680 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.69 · Expires 2026-08-01	Direct	Reported balance After 2019-11-20 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2019-11-20 · Disposition to issuer · Disposed 12,906 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.18 · Expires 2026-10-31	Direct	Reported balance After 2019-11-20 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2019-11-20 · Disposition to issuer · Disposed 31,210 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.18 · Expires 2027-01-30	Direct	Reported balance After 2019-11-20 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2019-11-20 · Disposition to issuer · Disposed 12,906 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $124.06 · Expires 2027-05-01	Direct	Reported balance After 2019-11-20 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2019-11-20 · Disposition to issuer · Disposed 11,384 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.41 · Expires 2027-07-31	Direct	Reported balance After 2019-11-20 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2019-11-20 · Disposition to issuer · Disposed 11,384 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.97 · Expires 2027-10-30	Direct	Reported balance After 2019-11-20 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2019-11-20 · Disposition to issuer · Disposed 26,308 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.26 · Expires 2028-01-29	Direct	Reported balance After 2019-11-20 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2019-11-20 · Disposition to issuer · Disposed 11,384 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.13 · Expires 2028-05-08	Direct	Reported balance After 2019-11-20 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2019-11-20 · Disposition to issuer · Disposed 18,257 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.91 · Expires 2028-07-30	Direct	Reported balance After 2019-11-20 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2019-11-20 · Disposition to issuer · Disposed 18,257 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.43 · Expires 2028-10-29	Direct	Reported balance After 2019-11-20 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2019-11-20 · Disposition to issuer · Disposed 18,257 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2019-11-20 · Disposition to issuer · Disposed 5,756 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 23 Instrument identity requires review; Table II rows are not merged. 1 source row Row 23 · 2019-11-20 · Disposition to issuer · Disposed 3,120 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 24 Instrument identity requires review; Table II rows are not merged. 1 source row Row 24 · 2019-11-20 · Disposition to issuer · Disposed 9,271 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 25 Instrument identity requires review; Table II rows are not merged. 1 source row Row 25 · 2019-11-20 · Disposition to issuer · Disposed 5,794 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 26 Instrument identity requires review; Table II rows are not merged. 1 source row Row 26 · 2019-11-20 · Disposition to issuer · Disposed 37,660 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.

F3: This option was fully exercisable.

F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.

F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 26, 2026 Filed Mar 2, 2026 18:09 UTC	Generate Biomedicines, Inc. GENB · Entity 1553	GrantStock Option (Right to Buy) · Derivative	29,561	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001193125-26-085952 · ownership.xml · derivative · entry 1 Vessey Rupert · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,561 Underlying: Common Stock · 29,561 shares Expires 2036-02-25 F1 · derivative.exercise_date: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document
October 30, 2025 Filed Nov 3, 2025 22:23 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantStock Options (Right to Buy) · Derivative	3,777	$0.00 Strike: $60.96	$0.00	Disclosure SEC source: 0000914190-25-000017 · form4.xml · derivative · entry 9 Vessey Rupert · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,777 Underlying: Common Stock · 3,777 shares Expires 2035-10-30 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. Read SEC document
October 30, 2025 Filed Nov 3, 2025 22:23 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantCommon Stock	1,640	$0.00	$0.00	Disclosure SEC source: 0000914190-25-000017 · form4.xml · nonDerivative · entry 1 Vessey Rupert · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,987 Read SEC document
October 24, 2024 Filed Oct 28, 2024 20:43 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantStock Options (Right to Buy) · Derivative	3,511	$0.00 Strike: $68.37	$0.00	Disclosure SEC source: 0001062993-24-018033 · form4.xml · derivative · entry 8 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,511 Underlying: Common Stock · 3,511 shares Expires 2034-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders. Read SEC document
October 24, 2024 Filed Oct 28, 2024 20:43 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantCommon Stock	1,462	$0.00	$0.00	Disclosure SEC source: 0001062993-24-018033 · form4.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,347 Read SEC document
October 26, 2023 Filed Oct 30, 2023 20:50 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantStock Options (Right to Buy) · Derivative	3,937	$0.00 Strike: $61.51	$0.00	Disclosure SEC source: 0001062993-23-019854 · form4.xml · derivative · entry 7 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires 2033-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders. Read SEC document
October 26, 2023 Filed Oct 30, 2023 20:50 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantCommon Stock	1,625	$0.00	$0.00	Disclosure SEC source: 0001062993-23-019854 · form4.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,885 Read SEC document
May 03, 2023 Filed May 4, 2023 21:51 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	50,385	$67.06	$3,378,818.10	Disclosure SEC source: 0000014272-23-000114 · wf-form4_168323704827586.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,751 F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $67.050 to $67.111, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionPerformance Shares · Derivative	44,541	$0.00	$0.00	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · derivative · entry 17 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 44,541 shares Expires 2023-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2023, subject to a Total Shareholder Return. F11 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2023, subject to a Total Shareholder Return. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionMarket Share Units · Derivative	7,147	$0.00	$0.00	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · derivative · entry 16 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,442 Underlying: Common Stock, $0.10 par value · 7,147 shares Expires 2026-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F5 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2022. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionMarket Share Units · Derivative	7,824	$0.00	$0.00	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · derivative · entry 15 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,651 Underlying: Common Stock, $0.10 par value · 7,824 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionMarket Share Units · Derivative	7,423	$0.00	$0.00	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · derivative · entry 14 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,425 Underlying: Common Stock, $0.10 par value · 7,423 shares Expires 2024-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Tax withholdingCommon Stock, $0.10 par value	25,565	$65.71	$1,679,876.15	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · nonDerivative · entry 12 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,136 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	OtherCommon Stock, $0.10 par value	5,438	$0.00	$0.00	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · nonDerivative · entry 11 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,701 F7 · shares: Adjustment to Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	44,541	$0.00	$0.00	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · nonDerivative · entry 10 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Amount represents distribution of performance shares earned under the 2020-2022 Long-Term Performance Award. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Tax withholdingCommon Stock, $0.10 par value	3,774	$65.71	$247,989.54	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · nonDerivative · entry 9 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,722 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	OtherCommon Stock, $0.10 par value	231	$0.00	$0.00	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · nonDerivative · entry 8 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,496 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	7,147	$0.00	$0.00	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · nonDerivative · entry 7 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2022. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Tax withholdingCommon Stock, $0.10 par value	4,659	$65.71	$306,142.89	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · nonDerivative · entry 6 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,118 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	OtherCommon Stock, $0.10 par value	1,284	$0.00	$0.00	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · nonDerivative · entry 5 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,777 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	7,824	$0.00	$0.00	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · nonDerivative · entry 4 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Tax withholdingCommon Stock, $0.10 par value	4,500	$65.71	$295,695.00	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · nonDerivative · entry 3 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,669 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	OtherCommon Stock, $0.10 par value	1,373	$0.00	$0.00	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,169 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document
March 10, 2023 Filed Mar 15, 2023 00:34 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	7,423	$0.00	$0.00	Disclosure SEC source: 0000014272-23-000068 · wf-form4_167884046832672.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · EVP & President, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document
December 02, 2022 Filed Dec 6, 2022 23:43 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	8,792	$0.00	$0.00	Disclosure SEC source: 0000014272-22-000204 · wf-form4_167037022076253.xml · derivative · entry 4 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,792 Underlying: Common Stock, $0.10 par value · 8,792 shares Expires 2023-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted stock unit vests in four equal annual installments beginning on December 2, 2020. Read SEC document
December 02, 2022 Filed Dec 6, 2022 23:43 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Tax withholdingCommon Stock, $0.10 par value	4,498	$81.13	$364,922.74	Disclosure SEC source: 0000014272-22-000204 · wf-form4_167037022076253.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,373 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document
December 02, 2022 Filed Dec 6, 2022 23:43 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	8,792	$0.00	$0.00	Disclosure SEC source: 0000014272-22-000204 · wf-form4_167037022076253.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in four equal annual installments beginning on December 2, 2020. Read SEC document
November 07, 2022 Filed Nov 10, 2022 01:38 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	8,491	$0.00 Strike: $38.41	$0.00	Disclosure SEC source: 0000014272-22-000198 · wf-form4_166804427924511.xml · derivative · entry 12 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 8,491 shares Expires 2028-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
November 07, 2022 Filed Nov 10, 2022 01:38 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	8,491	$0.00 Strike: $47.81	$0.00	Disclosure SEC source: 0000014272-22-000198 · wf-form4_166804427924511.xml · derivative · entry 11 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 8,491 shares Expires 2028-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
November 07, 2022 Filed Nov 10, 2022 01:38 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	8,491	$0.00 Strike: $44.70	$0.00	Disclosure SEC source: 0000014272-22-000198 · wf-form4_166804427924511.xml · derivative · entry 10 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 8,491 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
November 07, 2022 Filed Nov 10, 2022 01:38 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	21,288	$0.00 Strike: $72.42	$0.00	Disclosure SEC source: 0000014272-22-000198 · wf-form4_166804427924511.xml · derivative · entry 9 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 21,288 shares Expires 2027-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
November 07, 2022 Filed Nov 10, 2022 01:38 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	5,843	$0.00 Strike: $70.89	$0.00	Disclosure SEC source: 0000014272-22-000198 · wf-form4_166804427924511.xml · derivative · entry 8 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 5,843 shares Expires 2025-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
November 07, 2022 Filed Nov 10, 2022 01:38 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	45,910	$78.88	$3,621,380.80	Disclosure SEC source: 0000014272-22-000198 · wf-form4_166804427924511.xml · nonDerivative · entry 6 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,079 F1 · shares: 45,910 shares were sold to cover the exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $78.82 to $78.935, inclusive. The reporting person undertakes to provide the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F1 · price: 45,910 shares were sold to cover the exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $78.82 to $78.935, inclusive. The reporting person undertakes to provide the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
November 07, 2022 Filed Nov 10, 2022 01:38 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	8,491	$38.41	$326,139.31	Disclosure SEC source: 0000014272-22-000198 · wf-form4_166804427924511.xml · nonDerivative · entry 5 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 07, 2022 Filed Nov 10, 2022 01:38 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	8,491	$47.81	$405,954.71	Disclosure SEC source: 0000014272-22-000198 · wf-form4_166804427924511.xml · nonDerivative · entry 4 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 07, 2022 Filed Nov 10, 2022 01:38 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	8,491	$44.70	$379,547.70	Disclosure SEC source: 0000014272-22-000198 · wf-form4_166804427924511.xml · nonDerivative · entry 3 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 07, 2022 Filed Nov 10, 2022 01:38 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	21,288	$72.42	$1,541,676.96	Disclosure SEC source: 0000014272-22-000198 · wf-form4_166804427924511.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 07, 2022 Filed Nov 10, 2022 01:38 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	5,843	$70.89	$414,210.27	Disclosure SEC source: 0000014272-22-000198 · wf-form4_166804427924511.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 27, 2022 Filed Oct 31, 2022 21:21 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantStock Options (Right to Buy) · Derivative	865	$0.00 Strike: $295.77	$0.00	Disclosure SEC source: 0001415889-22-010916 · form4-10312022_021043.xml · derivative · entry 2 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865 Underlying: Common Stock · 865 shares Expires 2032-10-27 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/2022) or the date of Bio-Techne's 2023 annual meeting of shareholders. Read SEC document
October 27, 2022 Filed Oct 31, 2022 21:21 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantCommon Stock	338	$0.00	$0.00	Disclosure SEC source: 0001415889-22-010916 · form4-10312022_021043.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,565 Read SEC document
March 16, 2022 Filed Mar 18, 2022 21:50 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	8,490	$0.00 Strike: $38.41	$0.00	Disclosure SEC source: 0000014272-22-000090 · wf-form4_164764023320954.xml · derivative · entry 11 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,491 Underlying: Common Stock, $0.10 par value · 8,490 shares Expires 2028-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
March 16, 2022 Filed Mar 18, 2022 21:50 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	5,294	$0.00 Strike: $55.52	$0.00	Disclosure SEC source: 0000014272-22-000090 · wf-form4_164764023320954.xml · derivative · entry 10 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 5,294 shares Expires 2028-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
March 16, 2022 Filed Mar 18, 2022 21:50 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	12,233	$0.00 Strike: $54.29	$0.00	Disclosure SEC source: 0000014272-22-000090 · wf-form4_164764023320954.xml · derivative · entry 9 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 12,233 shares Expires 2027-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
March 16, 2022 Filed Mar 18, 2022 21:50 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionOption (right to buy) · Derivative	21,288	$0.00 Strike: $66.35	$0.00	Disclosure SEC source: 0000014272-22-000090 · wf-form4_164764023320954.xml · derivative · entry 8 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 21,288 shares Expires 2027-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
March 16, 2022 Filed Mar 18, 2022 21:50 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	43,228	$69.23	$2,992,674.44	Disclosure SEC source: 0000014272-22-000090 · wf-form4_164764023320954.xml · nonDerivative · entry 6 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,385 F2 · shares: 43,228 of the shares sold were to cover the exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $69.16 to $69.33, inclusive. The reporting person undertakes to provide the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F2 · price: 43,228 of the shares sold were to cover the exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $69.16 to $69.33, inclusive. The reporting person undertakes to provide the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
March 16, 2022 Filed Mar 18, 2022 21:50 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	8,490	$38.41	$326,100.90	Disclosure SEC source: 0000014272-22-000090 · wf-form4_164764023320954.xml · nonDerivative · entry 5 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 16, 2022 Filed Mar 18, 2022 21:50 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	12,233	$54.29	$664,129.57	Disclosure SEC source: 0000014272-22-000090 · wf-form4_164764023320954.xml · nonDerivative · entry 4 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 16, 2022 Filed Mar 18, 2022 21:50 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	5,294	$55.52	$293,922.88	Disclosure SEC source: 0000014272-22-000090 · wf-form4_164764023320954.xml · nonDerivative · entry 3 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 16, 2022 Filed Mar 18, 2022 21:50 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	21,288	$66.35	$1,412,458.80	Disclosure SEC source: 0000014272-22-000090 · wf-form4_164764023320954.xml · nonDerivative · entry 2 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 16, 2022 Filed Mar 18, 2022 21:50 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	31,331	$69.27	$2,170,298.37	Disclosure SEC source: 0000014272-22-000090 · wf-form4_164764023320954.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · EVP, Research & Early Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,308 F1 · shares: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $69.26 to $69.305, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $69.26 to $69.305, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.